News | February 24, 2022
Industry needs to ensure quality standards : S Aparna, Union Pharma Secretary
Collaboration in the industry needs to be institutionalised to drive the growth.
Collaboration in the industry needs to be institutionalised to drive the growth.
The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Evonik invests in start-up to improve patient recovery after open-chest surgery
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Subscribe To Our Newsletter & Stay Updated
